Not medical advice. Talk to your provider before using any peptide.
Full disclaimer
Exenatide (Byetta / Bydureon)39 residuesHGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPSEach bubble = one amino acid. Size = residue mass. Color = chemical class.Also known as: Byetta, Bydureon, Bydureon BCise
The first GLP-1 receptor agonist ever approved by the FDA, exenatide launched the entire drug class that now includes semaglutide and tirzepatide. Derived from exendin-4, a 39-amino-acid peptide found in Gila monster saliva, exenatide (Byetta, Bydureon) proved that targeting the incretin system could lower HbA1c by about 1% and produce meaningful weight loss in type 2 diabetes. The EXSCEL cardiovascular outcomes trial followed 14,752 patients for a median 3.2 years. AstraZeneca permanently discontinued both formulations in October 2024. No generic exists in the US. This page exists as a historical reference for patients transitioning to semaglutide or tirzepatide.
A 39-amino-acid peptide borrowed from lizard venom built the foundation for the biggest drug class in metabolic medicine. Exenatide (also sold as Byetta and Bydureon BCise, CAS 141758-74-9) is a synthetic version of exendin-4, originally isolated from the saliva of Heloderma suspectum, the Gila monster. It shares 53% sequence homology with human GLP-1 but resists cleavage by DPP-4, the enzyme that destroys native GLP-1 in roughly two minutes. The FDA approved Byetta in April 2005, making exenatide the first GLP-1 receptor agonist on the market. The twice-daily formulation required injection within 60 minutes before meals. Bydureon followed in 2012, using poly(D,L-lactide-co-glycolide) microspheres to deliver 2 mg once weekly. Across Phase 3 trials, Byetta reduced HbA1c by 0.8 to 1.0% from baseline and produced weight loss of 2 to 3 kg over 30 weeks (Buse et al.,; DeFronzo et al.)[1]. The EXSCEL cardiovascular outcomes trial enrolled 14,752 patients and confirmed non-inferiority to placebo for major adverse cardiac events (HR 0.91, 95% CI 0.83 to 1.00, p=0.06; Holman et al.)[3]. AstraZeneca permanently discontinued both products in October 2024. No FDA-approved generic exenatide exists. Grey-market or compounded sources cannot replicate Bydureon's microsphere technology. Patients should work with a prescriber to transition to semaglutide or tirzepatide.
Exenatide binds the GLP-1 receptor, a G-protein-coupled receptor expressed on pancreatic beta cells, throughout the GI tract, and in the hypothalamus. Activation triggers a glucose-dependent signaling cascade. When blood glucose is raised, exenatide amplifies insulin secretion from beta cells. When glucose is normal, the insulin signal fades; this glucose-dependent mechanism keeps hypoglycemia risk low during monotherapy. On the alpha-cell side, exenatide suppresses inappropriately raised glucagon output. That matters because excess glucagon drives hepatic glucose production, one of the core defects in type 2 diabetes. Gastric emptying slows substantially after each injection. Food reaches the small intestine more gradually, which flattens postprandial glucose spikes and contributes to satiety. In the brain, exenatide acts on hypothalamic appetite centers to reduce food intake. Users consistently report decreased cravings, particularly for carbohydrates. The exendin-4 backbone is what makes the drug work. Native GLP-1 has a half-life of about two minutes because DPP-4 chews through it almost immediately. Exenatide resists that enzymatic cleavage, extending its functional half-life to 2.4 hours (Byetta IR). The Bydureon formulation goes further; poly(D,L-lactide-co-glycolide) microspheres create a subcutaneous depot that sustains therapeutic plasma levels for a full week. Steady-state concentrations take 2 to 7 weeks to reach with weekly dosing (Byetta FDA Prescribing Information, Section 12.3).
FDA-approved GLP-1 RA for type 2 diabetes. Reduces HbA1c 0.8–1.0% and produces modest weight loss (~2–3 kg over 30 weeks). CV outcomes trial (EXSCEL, n=14,752) demonstrated non-inferiority to placebo but not superiority. 2024 sub-analysis shows increased HF hospitalization risk in patients with reduced LVEF (<40%); protective signal in preserved LVEF. Both formulations permanently discontinued Oct 2024.
EXSCEL: Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes (Holman et al., NEJM 2017; PMID 28910237)
EXSCEL missed superiority endpoint (HR 0.91, 95% CI 0.83–1.00, p=0.06). No dedicated weight-loss trials (non-diabetic population). Both products discontinued Oct 2024: historical data only. 2024 HF sub-analysis (PMID 39381950) showed heterogeneity of CV effect by LVEF; cautionary signal for HFrEF patients.
Historically positive for A1C reduction and weight loss in T2D patients. Nausea was the dominant complaint but usually resolved. Discussion has shifted almost entirely to retrospective or transition-focused since Oct 2024 discontinuation.
Science and community are well-aligned: both confirm meaningful HbA1c reduction, modest weight loss, and a GI side-effect profile that typically resolves. Community reported slightly larger weight-loss effects than RCT means (likely survivor bias and self-selected motivated users). Now moot for new patients: both formulations permanently discontinued Oct 2024.
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 5mcg | 2x Daily |
| Moderate | 10mcg | 2x Daily |
| Aggressive | 2mg | Weekly |
Both Byetta and Bydureon BCise were permanently discontinued in October 2024. No generic is available in the US. If you still have pens from before the discontinuation, check the expiration date and don't use anything past it. Byetta came as pre-filled pens. No reconstitution needed. The 5 mcg pen delivered 60 doses (one month at twice daily); the 10 mcg pen also delivered 60 doses. No bacteriostatic water, no insulin syringes, no mixing. Refrigerate before first use; after that, room temperature up to 30 degrees C for 30 days. Bydureon required reconstituting a microsphere suspension immediately before injection. It came in single-dose kits. The BCise autoinjector simplified this, but neither can be replicated by a compounding pharmacy. The biggest mistake most beginners made was timing. Inject within 60 minutes before the meal, not after. If you took it after eating, nausea got worse and glucose control suffered. Keep the two daily doses at least 6 hours apart. If you're on oral medications like antibiotics or birth control pills, take those at least one hour before your exenatide injection. The gastric emptying delay will slow their absorption otherwise. For anyone currently searching for exenatide: transition to semaglutide or tirzepatide with prescriber guidance.
Exenatide is prescribed as continuous long-term therapy for type 2 diabetes management. No cycling is needed. Discontinuation should be discussed with a prescribing physician, as glycemic control may deteriorate.
Exenatide was prescribed as continuous chronic therapy for type 2 diabetes: the underlying metabolic condition does not resolve, so therapy is indefinite. There is no evidence for cycling or receptor desensitization requiring drug holidays in clinical practice. The "cycling protocol" in the database (52 weeks on, 0 off) reflects standard clinical use. Glycemic control deteriorates upon discontinuation.
Or use the universal Peptide Calculator for any peptide.
Expected: HbA1c reduction of 0.8–1.0% from baseline; weight loss ~2–3 kg over 30 weeks
Monitor: HbA1c at 3 months and 6 months. Renal function at baseline and periodically. Lipase/amylase if abdominal pain develops.
Byetta pens should contain clear, colorless solution. Bydureon suspension will look cloudy after mixing. Discard if you see particles, discoloration, or the expiration date has passed.
Choose your injection site: abdomen, upper thigh, or back of the upper arm. Rotate sites each injection. Clean the area with an alcohol swab and let it dry.
For Byetta, a 31-gauge, 6mm or 8mm needle works well. Remove both the outer and inner needle caps.
For Byetta: dial to the prescribed dose (5 mcg during the first month, 10 mcg thereafter). Inject subcutaneously within 60 minutes before your meal. Hold the needle in the skin for 5 to 10 seconds after pressing the injection button, then withdraw.
For Bydureon BCise: the autoinjector delivers a fixed 2 mg dose once weekly. Press against the skin, activate, and hold for 15 seconds. A click confirms delivery. Same day each week, any time of day, with or without food.
Remove and safely dispose of the needle in a sharps container. Replace the pen cap. Store Byetta at room temperature (below 30 degrees C) after first use for up to 30 days. Bydureon kits stay refrigerated until ready to use.
Your second daily Byetta dose must be at least 6 hours after the first, also within 60 minutes before a meal. Take oral medications (antibiotics, oral contraceptives, warfarin, levothyroxine) at least 1 hour before the exenatide injection.
Since both products are discontinued, this guide is retained for historical reference.
N/A
Not approved or studied for IV use in clinical practice. Research studies have used IV infusion only for PK characterization.
N/A
Exenatide is a 39-amino acid peptide degraded by GI proteases. No oral formulation was developed (unlike semaglutide which uses a SNAC absorption enhancer for oral delivery). SC injection is the only practical route.
First-line T2D agent; exenatide was most commonly added as second-line to metformin. Complementary mechanisms (metformin: hepatic glucose production; exenatide: incretin effect). No hypoglycemia interaction.
Exenatide + basal insulin addresses both fasting hyperglycemia (insulin) and postprandial spikes + weight (exenatide). Reduce basal insulin dose by 20% when adding exenatide to prevent hypoglycemia.
Start exenatide 5 mcg BID; reduce current basal insulin by ~20% simultaneously
Common real-world combination for T2D. Additive HbA1c lowering. Carry fast-acting carbs: hypoglycemia risk is real when combining. Consider reducing sulfonylurea dose by 50% when adding exenatide.
Same GLP-1 receptor agonist drug class. Concurrent use doubles receptor stimulation without additional benefit and substantially increases GI side effects. Contraindicated.
Do not combineSame GLP-1 receptor agonist class. Concurrent use is contraindicated. No benefit over single agent; compounded GI adverse effects.
Do not combineGLP-1/GIP dual agonist. Contains GLP-1 receptor agonism: combining with exenatide is contraindicated for the same reasons as other GLP-1 agonists.
Do not combineMechanistic redundancy. Both increase active GLP-1 activity (DPP-4 inhibitors by blocking GLP-1 degradation; exenatide by direct GLP-1R activation). No additive glycemic benefit demonstrated; unnecessary dual therapy.
Pricing updated 2026-04-09
Black box warning: exenatide carries an FDA black box warning for medullary thyroid carcinoma risk. Rodent studies showed thyroid C-cell tumors with GLP-1 receptor agonist exposure at clinically relevant doses. The risk in humans remains uncertain, but exenatide is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Pancreatitis is the other serious concern. Rare but real. If persistent severe abdominal pain develops, exenatide should be stopped immediately and serum lipase and amylase checked. Levels exceeding three times the upper limit of normal warrant permanent discontinuation. The FDA label lists pancreatitis as a known risk for the entire GLP-1 receptor agonist class. Renal impairment has also been reported. Exenatide is renally eliminated and contraindicated when eGFR falls below 30 mL/min. Severe GI episodes (vomiting, diarrhea) can cause dehydration and precipitate acute kidney injury. A 2024 sub-analysis of the EXSCEL trial [6] flagged increased heart failure hospitalization risk in patients with reduced left ventricular ejection fraction (LVEF below 40%). Patients with preserved LVEF showed a protective signal. This distinction matters for anyone with existing cardiac issues. Nausea is the most commonly reported side effect. It hits hardest during the first four weeks at the 5 mcg dose and typically fades with continued use. In Phase 3 trials, roughly 40 to 50% of Byetta patients reported nausea during the first month. Community reports are consistent: most users describe it as manageable with small meals and proper injection timing (30 to 60 minutes before eating). About 10% of users couldn't tolerate even the starting dose. Vomiting and diarrhea affect a smaller subset, particularly during dose escalation from 5 to 10 mcg. Bydureon added its own issue: subcutaneous nodules at injection sites from the microsphere depot. These lumps can persist for 4 to 8 weeks and are visible or palpable. Rotating injection sites helps but doesn't eliminate them. Stop exenatide and contact a physician if you experience persistent severe abdominal pain, signs of an allergic reaction (rash, difficulty breathing, facial swelling), a neck mass or difficulty swallowing, or worsening kidney function. Pregnancy is a contraindication; animal data showed potential fetal harm, and no adequate human studies exist.
Verify Exenatide (Byetta / Bydureon) dosing and safety with a second opinion
Both Byetta and Bydureon BCise were permanently discontinued by AstraZeneca in October 2024. No FDA-approved generic exenatide exists in the US. Any currently available exenatide in the US market is sourced from grey-market, compounded, or imported sources: none of which carry the same quality assurance, sterility standards, or dosing precision as the original pharmaceutical products. The microsphere suspension technology used in Bydureon ER cannot be reliably replicated by compounding pharmacies.
| Test | When | Target |
|---|---|---|
| HbA1c | Baseline, then every 3 months for first year, then every 6 months if stable | <7.0% (individualize per patient; <8.0% acceptable in elderly or comorbid patients) |
| Fasting blood glucose / CGM | Self-monitoring per physician guidance; at least monthly during titration | Fasting: 80–130 mg/dL; postprandial: <180 mg/dL (ADA targets) |
| Renal function (SCr, eGFR) | Baseline, then annually or with clinical changes | eGFR ≥30 mL/min for continued use; contraindicated in ESRD |
| Serum lipase and amylase | If persistent severe abdominal pain occurs | Within normal laboratory reference range; 3× ULN warrants discontinuation |
| Body weight | Every clinic visit (monthly initially) | — |
| Thyroid exam / calcitonin | Baseline history; calcitonin only if symptomatic or high-risk for MTC | — |
| Liver enzymes (AST, ALT) | Baseline; annually or if symptoms develop | — |
Primary efficacy endpoint; target <7.0% for most T2D patients
Assess postprandial and fasting glucose response; titrate dose accordingly
Exenatide is renally eliminated; dose adjustment or discontinuation required if eGFR <30 mL/min
Rule out acute pancreatitis: a rare but serious GLP-1 RA class risk
Secondary endpoint; weight loss expected 2–5 kg over 6–12 months
Black box warning: medullary thyroid carcinoma risk (primarily rodent data; monitor in personal/family history of MTC or MEN2)
Improvement in hepatic enzymes seen with long-term use in clinical trials; rule out hepatotoxicity if elevated
Initial titration phase. Nausea is most common during this period and typically subsides. Mild appetite reduction begins. Fasting glucose starts to improve. Body adjusts to GLP-1 receptor activation.
Full Byetta dose reached. HbA1c begins to drop measurably. Weight loss of 1-2 kg is typical. GI side effects diminish for most patients. Postprandial glucose excursions are noticeably blunted.
Steady-state glycemic improvement. Phase 3 trials showed HbA1c reductions of 0.8-1.0% and weight loss of 2-3 kg by week 30. Appetite suppression stabilizes. Blood pressure may modestly decrease.
Sustained glycemic and weight benefits. Open-label extension data showed continued HbA1c improvement and progressive weight loss up to 5 kg over 82 weeks. Beta-cell function markers improve.
Long-term maintenance of glycemic control. Two-year data showed sustained HbA1c reduction, ongoing weight loss, and improvements in hepatic biomarkers (AST, ALT). Regular monitoring of renal function and pancreatic enzymes recommended.
Weeks 1 through 4: The starting dose is 5 mcg twice daily. Fasting glucose typically starts improving within the first week. Nausea peaks during this window and is the most common reason people consider stopping early. About 10% of users in community reports couldn't tolerate even this low dose. Eating small meals and timing injections before food (not after) makes a real difference. Weeks 5 through 12: Full Byetta dose of 10 mcg twice daily kicks in. HbA1c reductions become measurable on lab work. Weight loss of 1 to 2 kg is typical. Most users report that GI side effects drop off by week 6 or 7. Blood sugar readings after meals are noticeably flatter. Weeks 13 through 30: Steady-state glycemic benefit. Phase 3 trials showed HbA1c reductions of 0.8 to 1.0% from baseline and weight loss of 2 to 3 kg by this point. Community users described stable blood sugar, fewer carbohydrate cravings, and slow ongoing weight loss. Some hit a weight plateau around week 20. Weeks 30 through 52 and beyond: Open-label extension data from Blonde and colleagues [5] tracked progressive weight loss reaching 5 kg at 82 weeks. HbA1c stayed reduced. Liver enzymes (AST, ALT) improved. Long-term community users reported stable A1C and continued slow weight loss. The main complaints shifted from side effects to cost and insurance before the eventual discontinuation.
Titration phase at 5 mcg BID. Fasting glucose begins to improve. GI side effects peak during this window.
Nausea is common and expected. Most users describe it as manageable with small meals and proper timing. A minority (~10%) cannot tolerate even 5 mcg.
Full Byetta dose (10 mcg BID) reached. HbA1c reduction begins to be measurable on lab work. Weight loss of 1–2 kg typical.
Most users report GI side effects diminishing significantly. Appetite suppression stabilizes. Blood sugar readings noticeably improved.
Phase 3 trials: HbA1c reduction of 0.8–1.0% from baseline. Weight loss ~2–3 kg. Postprandial glucose excursions substantially reduced. Modest blood pressure decrease.
Users report stable blood sugar, reduced food cravings, and continued slow weight loss. Some report weight plateau around this point.
Open-label extension data (Blonde et al. 2006): progressive weight loss up to 5 kg over 82 weeks; sustained HbA1c reduction; improvement in hepatic transaminases (AST, ALT); beta-cell function markers show improvement.
Users who stayed on therapy long-term reported continued slow weight loss and stable A1C. Primary issue shifted to cost and insurance coverage prior to discontinuation.
Source: Byetta FDA Prescribing Information, Section 12.3: mean terminal half-life 2.4 hours
Loading the interactive decay curve.
Exenatide received FDA approval as Byetta in April 2005 for type 2 diabetes and as Bydureon (extended-release) in January 2012. Both carried full FDA approval with a black box warning for medullary thyroid carcinoma risk. They were prescription-only GLP-1 receptor agonists. AstraZeneca permanently discontinued both formulations in October 2024, citing a business decision rather than a safety concern. No FDA-approved generic or biosimilar exenatide exists in the United States. Biosimilar entry is projected for 2026 to 2028. Any exenatide currently available through grey-market peptide suppliers or non-US sources has not been evaluated for sterility, potency, or bioequivalence by the FDA. The Bydureon microsphere technology cannot be replicated by standard compounding pharmacies. Exenatide is prohibited by WADA in competition and out-of-competition for athletes. This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Peptide Schedule Research TeamReviewed Apr 20268 Citations
